New discovery may change the principles for treating cancer

Danish researchers from the University of Copenhagen and Herlev Hospital have made a discovery that may change the principles for treating certain types of cancer.

The discovery relates to the so-called telomeres that constitute the ends of human chromosomes. Short telomeres are related to unhealthy lifestyles, old age and the male gender - all of which are risk factors in terms of high mortality. Up until now, the assumption has been that short telomeres are related to ill health. The challenge for researchers worldwide has therefore been to find out whether or not the short telomeres were indeed a signifier or an indirect cause of increased mortality.

By studying more than 64,000 Danes from the Oesterbro Study and the Herlev/&Oesterbro Study - the largest telomere-study ever conducted - the researchers have reached the conclusion that the genetically determined length of telomeres has no influence on mortality in general. However, humans with genetically long telomeres have an increased risk of dying from cancer - which is the exact opposite of what the researchers expected to find. And this new knowledge may thus influence future cancer treatments.

"People have long telomeres because their cells are very apt at maintaining and repairing them. The disadvantage is that cancer cells are also very apt at maintaining and repairing their telomeres, which then prohibits the growth-inhibition that short telomeres would normally induce. If you are able to specifically target this repair process, in principle, you are then better able to stop cancer," says Stig Bojesen, Professor at the Faculty of Health and Medical Sciences at the University of Copenhagen and Chief Physician at Herlev Hospital, who has conducted the study in collaboration with Registrar Line Rode and Professor Boerge Nordestgaard.

The method is called telomerase-inhibition and has been studied as a possible cancer treatment since the mid-00s.

"So far, the method has not managed to fulfil the great expectations initially entertained. However, our discovery highlights that the principle of telomerase-inhibition should be afforded an important place in cancer treatment. The next challenge will be trying to locate more precisely, which cancer patients may benefit the most from such treatment," Stig Bojesen concludes.

Comments

  1. Vadim Shapoval Vadim Shapoval Ukraine says:

    Danish discovery relates to the so-called telomeres. Telomere activity is controlled by two mechanisms: erosion and addition. Addition is determined by the activity of telomerase. Telomerase consists of an RNA component (hTR) that acts to bind the telomere and a protein component (hTERT) that acts as a reverse transcriptase. Telomerase activity can be inhibited in cancerous cells and leads to a marked reduction in cellular viability and/or induces apoptosis of these cells. Anticancer approaches directed at telomerase inhibition are varied. Cancer costs us billions of dollars. It also costs us the people we love. One of the major costs of cancer is cancer treatment. Many treatment options for cancer exist, with the primary ones including surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy and palliative care. Cancer and its treatments can affect body systems. Cancer is when abnormal iron-overloaded cells divide in an uncontrolled way. Cancer is a single disease with a single cause. Cancer is a disease of iron-overloaded cells, the Father of Oncology says. At the cellular level, cancer occurs when cellular iron overload chaotically affects cellular molecules and organelles (RNA, DNA, chromosomes, mitochondria, lysosomes, etc). Different proteins are made up of different combinations of amino acids. This gives them their own unique 3D structure and function in the body. The DNA code contains instructions needed to make the proteins. Cellular iron overload creates chaotic mistakes/errors in DNA (and in hTERT), chromosomal abnormalities, chromothripsis and mitotic catastrophes. Direct intratumoral injections of iron-deficiency agents (ceramic needles) are needed when tumors and metastases cannot be removed with surgery (ceramic blades). Clinical personalized iron-deficiency methods can neutralize micrometastases. Professor Stig Bojesen and Professor Boerge Nordestgaard can make internationally significant iron discovery in oncology.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows cannabis as a genotoxic substance with cancer risks